Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
8.44
+0.24 (2.93%)
At close: Jun 26, 2026, 4:00 PM EDT
8.41
-0.03 (-0.36%)
After-hours: Jun 26, 2026, 7:01 PM EDT
Kyverna Therapeutics Employees
Kyverna Therapeutics had 130 employees as of December 31, 2025. The number of employees increased by 18 or 16.07% compared to the previous year.
Employees
130
Change (1Y)
18
Growth (1Y)
16.07%
Revenue / Employee
n/a
Profits / Employee
-$1,212,403
Market Cap
513.11M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 130 | 18 | 16.07% |
| Dec 31, 2024 | 112 | 16 | 16.67% |
| Dec 31, 2023 | 96 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 674 |
| Arvinas | 246 |
| ProKidney | 231 |
| Cabaletta Bio | 158 |
| Sutro Biopharma | 133 |
| Neurogene | 131 |
| C4 Therapeutics | 104 |
| Assembly Biosciences | 73 |
KYTX News
- 4 days ago - Kyverna Therapeutics appoints Ritesh Srivastava chief legal, compliance officer - TheFly
- 4 days ago - Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition - GlobeNewsWire
- 23 days ago - Kyverna Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 23 days ago - Kyverna Therapeutics presents updated COMPARE trial data at EULAR - TheFly
- 23 days ago - Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis - GlobeNewsWire
- 23 days ago - Kyverna Therapeutics Slides: Corporate presentation - Filings
- 4 weeks ago - Kyverna Therapeutics Transcript: AGM 2026 - Transcripts
- 5 weeks ago - Kyverna Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts